**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**



CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
  SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 7, 2009

**PFIZER INC.**
  (Exact name of registrant as specified in its charter)

|**Delaware**                                                                                       | **1-3619**               | **13-5315170**                      
|-------------------------------------------------------------------------------------------------- | ------------------------ | ------------------------------------
|(State or other Jurisdiction of incorporation)                                                     | (Commission File Number) | (I.R.S. Employer Identification No.)
|**235 East 42nd Street 
          New York, New York**(Address of principal executive offices)**** |                          | **10017**
        (Zip Code)        

> Registrant's telephone number, including area code:(212) 573-2323 ****
>       (Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended
  to simultaneously satisfy the obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):

[X ] Written communication pursuant to Rule 425 under the Securities
  Act (17 CFR 230.425)

[   ] Soliciting material pursuant to Rule 14a-12 under the Exchange
  Act (17 CFR 240.14a-12)

[   ] Pre-commencement communications pursuant to Rule 14d-2(b)
  under the Exchange Act (17 CFR 240.14d-2(b))

[   ] Pre-commencement communications pursuant to Rule 13e-4(c)
  under the Exchange Act (17 CFR 240.13e-4(c))



|Item 8.01                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Other Events
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ------------
|On April 7, 2009, Pfizer Inc. issued a press release announcing the operating
        structure of the Company and certain senior leadership positions that
        will be effective upon the closing of its acquisition of Wyeth. A copy
        of the press release is attached hereto as Exhibit 99.1 and is incorporated
        by reference herein. On April 7, 2009, Pfizer also distributed a letter
        from Pfizer Chairman and CEO, Jeffrey B. Kindler, to Pfizer's employees.
        A copy of the letter to employees is attached hereto as Exhibit 99.2 and
        is incorporated by reference herein..



|**Item 9.01** | **Financial Statements and Exhibits.** | 
|------------- | -------------------------------------- | 

|(d) Exhibits |                                               | 
|------------ | --------------------------------------------- | 
|99.1         | Pfizer Inc. Press Release dated April 7, 2009 | 
|99.2         | Letter to Pfizer Employees                    | 





**SIGNATURE**

Under the requirements of the Securities Exchange Act of 1934, the registrant
  has caused this report to be signed on its behalf by the authorized undersigned.

|                     |  | PFIZER INC.                                                                                       
|-------------------- |  | --------------------------------------------------------------------------------------------------
|                     |  |                                                                                                   
|                     |  | By: /s/  Matthew Lepore
         Matthew Lepore                                                   
|                     |  | Title: Vice President, Chief Counsel - Corporate Governance,
        and Assistant General Counsel
|Dated: April 7, 2009 |  |                                                                                                   

> EXHIBIT INDEX

|Exhibit No. | Description                                  
|----------- | ---------------------------------------------
|99.1        | Pfizer Inc. Press Release dated April 7, 2009
|99.2        | Letter to Pfizer Employees